Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in ALS
NCT00231140Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of thalidomide in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Long-term safety and tolerability of thalidomide and Comparison of total number of adverse events and abnormal laboratory tests. Started Dec 2005; status: terminated.
02
Drugs
thalidomide
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT00231140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00231140.